Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to 0.72.

  • Allogene Therapeutics' Equity Ratio fell 891.24% to 0.72 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.72, marking a year-over-year decrease of 891.24%. This contributed to the annual value of 0.77 for FY2024, which is 344.23% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Equity Ratio stood at 0.72, which was down 891.24% from 0.73 recorded in Q2 2025.
  • Allogene Therapeutics' Equity Ratio's 5-year high stood at 0.91 during Q2 2021, with a 5-year trough of 0.72 in Q3 2025.
  • Its 5-year average for Equity Ratio is 0.82, with a median of 0.8 in 2023.
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 300.02% in 2021, then crashed by 1078.81% in 2023.
  • Allogene Therapeutics' Equity Ratio (Quarter) stood at 0.88 in 2021, then fell by 7.81% to 0.81 in 2022, then dropped by 1.83% to 0.8 in 2023, then decreased by 3.44% to 0.77 in 2024, then fell by 6.81% to 0.72 in 2025.
  • Its last three reported values are 0.72 in Q3 2025, 0.73 for Q2 2025, and 0.76 during Q1 2025.